{ "release_version": "10.85.0", "research_window": { "from_utc": "2026-09-22T03:57:18Z", "through_utc": "2026-09-22T09:57:32Z", "precision": "second", "timezone": "America/Indiana/Indianapolis" }, "review_completed_at": "2026-09-22T10:08:28Z", "changes": [ { "entry_id": "NAT-2026-09-22-001", "kind": "added", "before": null, "after": { "id": "NAT-2026-09-22-001", "scope": "national", "date": "2026-09-22", "display_date": "September 22, 2026", "title": "FDIC proposes new bank-merger review and deemed-approval framework", "dek": "The proposal would revise competitive analysis, create a letter filing and deemed approval for qualifying de minimis transactions, and tailor other review requirements; it is not final or implemented.", "facts": [ "The FDIC published a proposed Bank Merger Act rule on September 22 after board approval on September 17. Comments are due November 23, 2026; the notice does not establish a final rule, effective date or approval of any particular merger.", "For qualifying de minimis transactions, the proposal would create a shorter letter filing and deemed approval after specified processing periods. Eligibility would depend on transaction, size, condition and supervisory criteria, and the FDIC could remove a filing from expedited processing when adverse information, a material protest or other good cause warrants more review.", "The proposal would revise competitive-effects screening to account for credit-union shares and centrally booked deposits, add safe harbors, and codify how the FDIC evaluates statutory factors including competition, financial resources, managerial resources, convenience and needs, financial stability, anti-money-laundering effectiveness and Deposit Insurance Fund risk.", "The FDIC says the changes are intended to make review faster, more predictable and better aligned with modern competition while retaining scrutiny where risks warrant it. Those are the agency's stated aims; the proposal has not shortened an actual review, approved a merger or produced a measured competition, stability or community outcome." ], "significance": "If finalized, the rule would materially change how the federal deposit insurer screens and times bank-merger applications, including when a small transaction can proceed without an affirmative approval order. The competitive, supervisory and community effects depend on the final text and later cases.", "goalpost": "The FDIC argues that the framework recognizes credit unions and modern deposit booking, reduces unnecessary burden and preserves case-specific escalation. Commenters can test the de minimis thresholds, deemed-approval safeguards, market definitions and statutory-factor standards; the final rule, implementation data, merger outcomes and competition or service measurements are the goalposts.", "maybe_therefore": "Maybe a more tailored process speeds low-risk combinations while focusing staff on consequential cases, or deemed approval and broader safe harbors could reduce scrutiny that later proves important. Therefore the FDIC has proposed a detailed merger-review framework for comment—not adopted it, approved any merger under it or demonstrated its effects.", "evidence": "complete Federal Register proposed rule; formal proposal and comment deadline documented, final rule, implementation and outcomes unresolved", "tags": [ "FDIC", "bank mergers", "Bank Merger Act", "competition", "proposed rule" ], "institutions": [ "Federal Deposit Insurance Corporation", "Federal Register" ], "sources": [ "federal_register_fdic_merger_proposal_sep22" ], "checked_at": "2026-09-22 5:57 AM EDT", "pack_filename": "NAT-2026-09-22-001.zip", "pack_path": "artifacts/entries/NAT-2026-09-22-001.zip", "review_status": "current-standard-reviewed" }, "summary": "Added the proposed FDIC merger-review framework without inferring adoption, an approved merger or measured effects." }, { "entry_id": "NAT-2026-09-22-002", "kind": "added", "before": null, "after": { "id": "NAT-2026-09-22-002", "scope": "national", "date": "2026-09-22", "display_date": "September 22, 2026", "title": "FDIC proposes State Bank Parity rule for cross-state services", "dek": "The proposal would generally give out-of-state state banks the same host-state-law treatment as national banks, including when services are provided without a branch; it does not itself preempt a specific state law.", "facts": [ "The FDIC published a proposed State Bank Parity rule on September 22, with comments due November 23, 2026. It remains a proposal with no final rule or effective date.", "Under the proposal, when a host-state law does not apply to an out-of-state national bank, that law likewise would not apply to an out-of-state state bank providing services in the host state, whether or not the state bank has a branch there; the bank's home-state law would instead apply.", "The proposed interpretation would cover host-state laws in areas named by the regulation, including community reinvestment, consumer protection, fair lending and establishment of intrastate branches. The FDIC says the rule would not determine that any particular state law is federally preempted and would not change state-bank loan-interest authority under section 27 of the Federal Deposit Insurance Act.", "The FDIC identifies online and mobile banking and litigation over Illinois's Interchange Fee Prohibition Act as reasons to clarify parity. Its analysis estimates possible compliance-cost and interchange-fee effects under assumptions about that law, but says precise effects are uncertain; no avoided cost, merchant transfer or consumer outcome has yet been measured under the proposed rule." ], "significance": "The proposal would affect which state's consumer, fair-lending and banking rules govern state-chartered banks serving customers across state lines. It could reduce competitive differences with national banks while also limiting application of some host-state protections, depending on separate preemption law and the final rule.", "goalpost": "The FDIC says Congress intended parity between national and state banks and that branchless digital banking makes the existing text uncertain. The scope of applicable state laws, preemption decisions, final language, litigation, bank compliance changes and measured effects on merchants and consumers are the tests.", "maybe_therefore": "Maybe the proposal removes an unintended charter disadvantage and creates predictable nationwide service rules, or it may displace host-state safeguards without sufficient local accountability. Therefore the FDIC has proposed a parity interpretation for public comment—not preempted a named state law, finalized the rule or established its economic effects.", "evidence": "complete Federal Register proposed rule; proposed interpretation, limits, assumptions and comment deadline documented, final rule and effects unresolved", "tags": [ "FDIC", "state banks", "federal preemption", "consumer protection", "proposed rule" ], "institutions": [ "Federal Deposit Insurance Corporation", "Federal Register" ], "sources": [ "federal_register_fdic_state_parity_proposal_sep22" ], "checked_at": "2026-09-22 5:57 AM EDT", "pack_filename": "NAT-2026-09-22-002.zip", "pack_path": "artifacts/entries/NAT-2026-09-22-002.zip", "review_status": "current-standard-reviewed" }, "summary": "Added the proposed state-bank parity interpretation without treating it as a preemption ruling or final rule." }, { "entry_id": "NAT-2026-09-22-003", "kind": "added", "before": null, "after": { "id": "NAT-2026-09-22-003", "scope": "national", "date": "2026-09-22", "display_date": "September 22, 2026", "title": "GSA proposes streamlined Federal Supply Schedule ordering rules", "dek": "The proposal would move schedule-ordering procedures from the FAR to GSA's own regulation and remove or simplify several order-level steps; comments are due October 22.", "facts": [ "GSA published a proposed rule on September 22 to move Federal Supply Schedule ordering procedures from FAR subpart 8.4 to GSAR part 538 as part of the administration's Revolutionary FAR Overhaul. Comments are due October 22, 2026; no final or effective rule exists.", "The proposal would organize order placement primarily by dollar threshold and state that FAR parts 5, 6, 14, 15, 16 and 19 do not apply to the new subpart unless another provision says otherwise. It also says schedule requests for quotations are not negotiated procurements or source selections and generally would not require evaluation plans, quotation scoring or a competitive range.", "For some lower-value acquisitions the proposed text would allow oral orders before written confirmation. For schedule-priced products, services or solutions, it would not require a new responsibility determination or a new fair-and-reasonable-price determination at the order or blanket-purchase-agreement level because GSA says those determinations occur at contract level; separate requirements would remain for order-level materials and sole-source justifications.", "GSA says the change would improve speed, readability, flexibility and administrative efficiency. Those benefits have not been measured under this proposal, and the notice does not document an executed procurement, savings, competition result or contractor outcome." ], "significance": "Federal Supply Schedule procedures govern recurring purchases across the government. Moving and simplifying them could materially change how agencies solicit, evaluate and document orders, but the practical balance between speed, competition, price discipline and small-business access remains prospective.", "goalpost": "GSA presents the proposal as an essential-requirements approach that relies on contract-level vetting while preserving threshold-based competition and sole-source controls. The final GSAR text, agency guidance, procurement files, protest decisions, cycle time, participation, prices and independently measured savings are the goalposts.", "maybe_therefore": "Maybe removing procedures designed for other acquisition methods lets schedule buyers act faster without sacrificing safeguards already built into the contracts, or reduced order-level documentation could make weaknesses harder to detect. Therefore GSA has proposed a streamlined framework—not implemented it or shown that it saves money while preserving competition and accountability.", "evidence": "complete Federal Register proposed rule; proposed procedures and comment deadline documented, final rule, implementation and procurement outcomes unresolved", "tags": [ "GSA", "Federal Supply Schedule", "federal procurement", "FAR", "proposed rule" ], "institutions": [ "General Services Administration", "Office of Federal Procurement Policy", "Federal Register" ], "sources": [ "federal_register_gsa_fss_ordering_proposal_sep22" ], "checked_at": "2026-09-22 5:57 AM EDT", "pack_filename": "NAT-2026-09-22-003.zip", "pack_path": "artifacts/entries/NAT-2026-09-22-003.zip", "review_status": "current-standard-reviewed" }, "summary": "Added the proposed GSA schedule-ordering framework without inferring implementation, savings or procurement outcomes." }, { "entry_id": "NAT-2026-09-22-004", "kind": "added", "before": null, "after": { "id": "NAT-2026-09-22-004", "scope": "national", "date": "2026-09-22", "display_date": "September 22, 2026", "title": "FDA conditionally adopts broader nonclinical-testing terminology", "dek": "A direct final rule would replace animal-, preclinical- and in-vitro-specific terms with broader nonclinical terminology, but it takes effect only if FDA receives no significant adverse comment; a companion proposal preserves notice-and-comment review.", "facts": [ "FDA published a direct final rule and a substantively paired proposed rule on September 22. Comments are due December 7, 2026; the direct final rule is scheduled for February 4, 2027 only if FDA receives no significant adverse comment and confirms the effective date.", "The paired texts would replace multiple regulatory references to animal tests or studies, preclinical tests and in vitro tests with nonclinical terminology. New definitions encompass in vivo studies, cell-based assays, computer modeling and other nonhuman or human-biology-based methods conducted outside the body.", "FDA says the changes impose no new testing requirement, remove an undue textual emphasis on animal testing as the only methodology, and may foster new approach methodologies, improve predictivity and reduce animal use while maintaining safety and effectiveness standards. These are the agency's rationale and anticipated benefits, not measured outcomes.", "If FDA receives significant adverse comments, it says it will withdraw the affected direct-final provisions before the effective date and use the companion proposal to continue rulemaking. No provision was effective at cutoff, and the terminology change does not by itself validate a method, approve a product or replace evidence requirements for a particular submission." ], "significance": "The rulemaking would modernize the vocabulary across drug and biologic regulations so non-animal methods are not excluded by animal-specific wording. Whether it materially changes sponsor behavior, FDA acceptance, safety prediction or animal use depends on method validation, guidance and implementation beyond the textual amendments.", "goalpost": "FDA says broader terminology reflects statutory recognition of nonclinical tests and supports alternatives without weakening safety standards or adding requirements. Adverse comments, the confirmation or withdrawal notice, later guidance, accepted submissions, validation results, animal-use data and product-safety outcomes are the tests.", "maybe_therefore": "Maybe terminology that expressly includes modeling and human-biology methods removes a real regulatory signal favoring animal studies, or wording alone may change little without validated methods and review standards. Therefore FDA conditionally issued paired rulemaking to broaden terminology—not an effective mandate, blanket acceptance of alternatives or demonstrated reduction in animal use.", "evidence": "complete paired Federal Register direct-final and proposed rules; conditional lifecycle, definitions and agency rationale documented, effective status and outcomes unresolved", "tags": [ "FDA", "nonclinical testing", "animal testing", "new approach methodologies", "direct final rule" ], "institutions": [ "Food and Drug Administration", "Department of Health and Human Services", "Federal Register" ], "sources": [ "federal_register_fda_nonclinical_direct_final_sep22", "federal_register_fda_nonclinical_proposal_sep22" ], "checked_at": "2026-09-22 5:57 AM EDT", "pack_filename": "NAT-2026-09-22-004.zip", "pack_path": "artifacts/entries/NAT-2026-09-22-004.zip", "review_status": "current-standard-reviewed" }, "summary": "Added FDA's paired conditional rulemaking without treating the direct final rule as effective or alternatives as validated." } ] }